Newsfeeds - Spark Newswire

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

Today, 6:44 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABT

2 minute read

News

Novartis and Medicines for Malaria Venture Announce Decision to Move to Phase 3 Study for Novel Ganaplacide/lumefantrine-SDF Combination in Adults and Children With Malaria

By Charles Gross

Today, 6:44 AM

As the threat of resistance to current malaria treatments grows1,2, Novartis and MMV announce the decision to progress ganaplacide/lumefantrine- solid dispersion formulation (SDF) into Phase 3 development for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

NVS

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 6:44 AM

ABBV

1 minute read

FDA
News

Novartis Highlights Advances With Kisqali, Iptacopan, Scemblix And YTB323 Data At SABCS And Ash

By Benzinga Newsdesk

Today, 6:44 AM

First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and serious

NVS

1 minute read

Novartis Weighs Ophthalmology, Respiratory Unit Sales

By Charles Gross

Today, 6:44 AM

-Bloomberg https://www.bloomberg.com/news/articles/2022-11-16/novartis-is-said-to-weigh-ophthalmology-respiratory-unit-sales#xj4y7vzkg

NVS

1 minute read

BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023

By Vandana Singh

Today, 6:44 AM

BioNTech SE (NASDAQ:BNTX) said that its first mRNA manufacturing facility in Singapore will be operational in late 2023, with the…

BNTX

2 minute read

After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns

By Vandana Singh

Today, 6:44 AM

The European Medicine Agency’s safety committee recommended that a group of JAK inhibitors for chronic inflammatory disorders be only used…

ABBV

2 minute read

US Stock Futures Down; Big Tech Earnings In Focus

By Lisa Levin

Today, 6:44 AM

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the three major indices recorded their best week since June.

AZN

1 minute read

Novartis Q3 EPS $1.58 Beats $1.57 Estimate, Sales $12.54B Miss $12.99B Estimate

By Benzinga Newsdesk

Today, 6:44 AM

Novartis (NYSE:NVS) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.57 by 0.64 percent. This is a 7.6 percent decrease over earnings of $1.71 per share from the same period

NVS

1 minute read

News

Novartis Announced Investigational Oral Monotherapy Iptacopan Demonstrates Clinically Meaningful Superiority over Anti-C5 Treatment in Phase III APPLY-PNH sStudy

By Charles Gross

Today, 6:44 AM

Novartis today announced the pivotal Phase III APPLY-PNH trial met its two primary endpoints, showing investigational oral monotherapy iptacopan was superior to anti-C5 therapies (eculizumab or ravulizumab) in adults with paroxysmal nocturnal hemoglobinuria (PNH) experiencing residual anemia despite prior treatment with anti-C5s1.

NVS